Palmitoyl Dipeptide-6 vs Argireline
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6Skin & Cosmetic
Argireline- Summary
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
- Half-Life
- Not applicable (topical)
- N/A — topical application; effect duration linked to formulation contact time
- Admin Route
- Topical
- Topical
- Research
- —
- —
- Typical Dose
- 0.005–0.05% in formulation
- 5–10% concentration
- Frequency
- Once or twice daily
- Twice daily
- Key Benefits
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- Reduces depth of dynamic expression wrinkles 17–27%
- Non-invasive topical Botox alternative
- Smooths forehead, eye area, nasolabial fold lines
- Widely studied — published clinical efficacy data
- Synergistic with SNAP-8 for enhanced effect
- Reduces fine lines around eyes (crow's feet)
- Improves skin smoothness and texture
- Well tolerated across all skin types
- Side Effects
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Generally very well tolerated
- At >10%: temporary eyelid/brow ptosis (drooping)
- Rare: mild redness in sensitive skin
- No systemic absorption at cosmetic doses
- Stacks With
- —
- —